Recent advances in hematopoietic gene therapy for genetic disorders

Arch Pediatr. 2023 Nov;30(8S1):8S24-8S31. doi: 10.1016/S0929-693X(23)00224-5.ABSTRACTHematopoietic gene therapy is based on the transplantation of gene-modified autologous hematopoietic stem cells and since the inception of this approach, many technological and medical improvements have been achieved. This review focuses on the clinical studies that have used hematopoietic gene therapy to successfully treat several rare and severe genetic disorders of the blood or immune system as well as some non-hematological diseases. Today, in some cases hematopoietic gene therapy has progressed to the point of being equal to, or better than, allogeneic bone marrow transplant. In others, further improvements are needed to obtain more consistent efficacy or to reduce the risks posed by vectors or protocols. Several hematopoietic gene therapy products showing both long-term efficacy and safety have reached the market, but economic considerations challenge the possibility of patient access to novel disease-modifying therapies. © 2023 Published by Elsevier Masson SAS on behalf of French Society of Pediatrics.PMID:38043980 | DOI:10.1016/S0929-693X(23)00224-5
Source: Archives de Pediatrie - Category: Pediatrics Authors: Source Type: research